Experience

Davis Polk advised the representative of the underwriters in connection with the $181 million public offering of 4,025,000 shares of common stock of Spark Therapeutics, Inc. (“Spark”),…

Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Nevro Corp. of $172.5 million aggregate principal amount of its 1.75%…

Davis Polk advised the joint bookrunners in connection with a Rule 144A offering by The Medicines Company of $402.5 million aggregate principal amount of 2.75% convertible senior notes due…

Davis Polk advised Aetna Inc. on its SEC-registered notes offering of $13 billion aggregate principal amount of senior notes in eight series, consisting of $500 million aggregate principal…

Davis Polk advised the representatives of the initial purchasers on Rule 144A/Regulation S offerings by Mylan N.V. (“Mylan”) of $1.0 billion aggregate principal amount of its 2.500% senior…

Davis Polk advised the joint book-running managers in connection with a $41.4 million SEC-registered common stock offering of 1,926,250 shares of common stock of Loxo Oncology, Inc…

Davis Polk is advising Anacor Pharmaceuticals, Inc. on its approximately $5.2 billion acquisition by Pfizer Inc. The closing of the transaction, which is expected in the third quarter…

Davis Polk advised the representatives of the underwriters, in connection with an SEC-registered offering by AbbVie Inc. (“AbbVie”) of $7.8 billion aggregate principal amount of senior…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s…

Davis Polk advised Anacor Pharmaceuticals, Inc. in connection with its offering of $287.5 million aggregate principal amount of its 2.00% convertible senior notes due 2023 to qualified…